Verastem, Inc. (NASDAQ: VSTM) shares gained about 6.4% to $8.25 on Wednesday, making it one of the top performers in the PRISM Women’s Health Index….
April 07, 2026
Greenwich LifeSciences Files New GP2 Patent Claims That Could Double Its Breast Cancer Market
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) has filed new patent claims for its breast cancer immunotherapy GLSI‑100 (GP2 + GM‑CSF), based on statistically significant immune‑response and recurrence‑rate…
March 25, 2026
Corcept Therapeutics Soars as FDA Greenlights Relacorilant for Hard‑to‑Treat Ovarian Cancer
Corcept Therapeutics Inc. (NASDAQ: CORT) stock is surging after the FDA approved its cancer drug relacorilant in combination with nab‑paclitaxel for adults with platinum‑resistant ovarian…
Citius Oncology (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (NASDAQ: CTXR), has signed an exclusive European Union distribution agreement for its oncology immunotherapy LYMPHIR™…